Neurofeedback for Borderline Personality Disorder
The goal of this study is to evaluate whether rtfMRI-nf training to increase the amygdala response to positive memories may serve as an intervention for borderline personality disorder.
Conditions:
🦠 Borderline Personality Disorder
🗓️ Study Start (Actual) 2 September 2022
🗓️ Primary Completion (Estimated) 31 August 2025
✅ Study Completion (Estimated) 31 August 2025
👥 Enrollment (Estimated) 100
🔬 Study Type INTERVENTIONAL
📊 Phase NA
Locations:
📍 Pittsburgh, Pennsylvania, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * right-handed adults (ages 18 - 55) with a primary diagnosis of Borderline Personality Disorder according to diagnostic criteria in the Structured Interview for DSM Personality Disorders
    • * must be able to give written informed consent prior to participation
    • * unmedicated or stable on an SSRI antidepressant regime (at least 3 weeks to ensure symptoms are stable)
    • * English speaking

    Exclusion Criteria:

    • * have a clinically significant or unstable cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder
    • * Current moderate or severe DSM-V alcohol or substance use disorder, with the exception of nicotine or caffeine. Clinician will access subjects' alcohol and substance use on a case-by-case to determine whether specific cases of mild alcohol or substance use would also interfere with the effects of the intervention.
    • * have a history of traumatic brain injury
    • * are unable to complete MRI scan due to claustrophobia or general MRI exclusions (e.g., shrapnel inside body)
    • * are currently pregnant or breast feeding
    • * are unable to complete questionnaires written in English
    • * current (within 3 weeks of testing) use of any antipsychotics, benzodiazepines, beta-blockers, or other medications (except SSRI antidepressants) likely to influence cerebral blood flow. Effective medications will not be discontinued for the purposes of the study. Inclusion of patients on stable antidepressant medications was decided in order to allow generalization towards a real world population
    • * have a DSM-5 diagnosis of psychotic or organic mental disorder
    • * have any eye problems or difficulties in corrected vision.
    • * Serious suidicial ideation
Ages Eligible for Study: 18 Years to 55 Years (ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 25 May 2022
  • First Submitted that Met QC Criteria 25 May 2022
  • First Posted 1 June 2022

Study Record Updates

  • Last Update Submitted that Met QC Criteria 3 July 2024
  • Last Update Posted 5 July 2024
  • Last Verified July 2024